Blockchain Registration Transaction Record

Silo Pharma to Present PTSD Nasal Therapy Data at IPAC-RS Forum

Silo Pharma advances PTSD nasal therapy SPC-15 with stability data, participates in IPAC-RS 2026 Nasal Innovation Forum, targeting CNS disorders.

This news matters because it signals tangible progress in the development of SPC-15, a potential new treatment for PTSD that leverages a nose-to-brain delivery method, which could offer faster onset and fewer side effects than current options. For patients suffering from PTSD, a condition with limited effective treatments, this could mean a new, more accessible therapy. For investors, Silo's stability data and forum participation are positive indicators of the company's scientific rigor and market potential, especially as it diversifies into cryptocurrency. The forum also provides networking opportunities that could lead to partnerships and accelerate clinical development, potentially bringing this innovative treatment closer to market.